Adiponectin is associated with improvement of endothelial function after rosiglitazone treatment in non-diabetic individuals with metabolic syndrome

• Published in: Atherosclerosis Vol. 195; no. 1; pp. 138 - 146
• Main Authors: Bahia, Luciana, Aguiar, Luiz Guilherme K., Villela, Nivaldo, Bottino, Daniel, Godoy-Matos, Amelio F., Geloneze, Bruno, Tambascia, Marcos, Bouskela, Eliete
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier Ireland Ltd 01.11.2007; Elsevier
• Subjects: Acetylcholine - pharmacology; Adipokines; Adiponectin; Adiponectin - biosynthesis; Adiponectin - metabolism; Adult; Associated diseases and complications; Atherosclerosis (general aspects, experimental research); Biological and medical sciences; Blood and lymphatic vessels; C-Reactive Protein - metabolism; Cardiology. Vascular system; Cardiovascular; Cardiovascular system; Diabetes. Impaired glucose tolerance; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Endothelium; Endothelium, Vascular - drug effects; Endothelium, Vascular - metabolism; Female; Glucose Tolerance Test; Humans; Hypertension - complications; Hypoglycemic Agents - pharmacology; Insulin - metabolism; Investigative techniques of hemodynamics; Investigative techniques, diagnostic techniques (general aspects); Male; Medical sciences; Metabolic syndrome; Metabolic Syndrome - drug therapy; Middle Aged; Nitroprusside - pharmacology; Rosiglitazone; Thiazolidinediones - pharmacology; Rosiglitazone; Adipokines; Metabolic syndrome; Adiponectin; Endothelium; Endocrinopathy; Pancreatic hormone; Vasodilator agent; Cardiovascular disease; Vasodilation; Vascular disease; Vasomotricity; Hypoglycemic agent; Vascular resistance; Atherosclerosis; Fibrinogen; C reactive protein; Human; Diabetes mellitus; Metabolic diseases; Thiazolidinedione derivatives; Inflammation; Insulin; Blood flow; Sodium nitroprusside; Treatment; Risk factor; Neurotransmitter; Antihypertensive agent; Acetylcholine; Hemodynamics; Comparative study; Plethysmography; Sensitizer
• ISSN: 0021-9150; 1879-1484; 1879-1484
• DOI: 10.1016/j.atherosclerosis.2006.09.003

The risks of metabolic syndrome (MetSyn) rely on the interaction between insulin resistance, metabolic abnormalities, inflammation and vascular dysfunction. Insulin sensitizers counteract some of these abnormalities. The objective of this study was to evaluate the effects of rosiglitazone (ROSI) on vascular reactivity, adipokines and inflammatory markers in a group of non-diabetic subjects with MetSyn. Thirty subjects with NCEP-ATPIII criteria for MetSyn and eight healthy subjects were studied at baseline and 18 subjects with MetSyn were treated with ROSI 8 mg/day for 24 weeks. Venous occlusion plethysmography exams before and during intra-arterial infusions of acetylcholine and sodium nitroprusside were performed to assess endothelial-dependent and independent vasodilation. Forearm blood flow (FBF) and vascular resistance (VR) responses were analyzed. Treatment with ROSI improved endothelial function (235% increment in FBF; p < 0.01 and 56% decrement in VR; p = 0.01), adiponectin (7.3[3.6–17.9] versus 37.9[19.3–42.4]; p < 0.01), HOMA-IR (3.5 ± 1.2 versus 2.7 ± 1.6; p < 0.05), C-reactive protein (CRP) (1.05[0.57–2.07] versus 0.3[0.2–0.8]; p < 0.01) and fibrinogen (3.1 ± 0.73 versus 2.62 ± 0.64; p < 0.05) levels. The difference between groups on endothelial-dependent vasodilation, adiponectin and CRP levels disappeared after treatment and the improvement of endothelial function was associated with the increment of adiponectin levels. ROSI treatment restored endothelial function in MetSyn subjects, probably through an adiponectin-mediated process.